Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
Tiziana Life Sciences (TLSA) will present at the Jefferies Healthcare Conference in London on November 18, 2026. The company will discuss its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis, which met primary endpoints and showed clinical improvements. Management will also be available for one-on-one meetings.
How this was made
The 30-second read
Why it matters
The Phase 2a results provide the first efficacy readout for foralumab in secondary progressive MS, a key milestone for the company's pipeline.
Market read
Positive trial data may trigger short‑term buying interest and set the stage for future funding rounds.
What to watch
Potential regulatory delays and competition from other anti‑CD3 programs could temper upside.
Background
Tiziana Life Sciences (TLSA) is a clinical‑stage biotech focused on intranasal delivery of immunomodulatory antibodies.
Ticker impact
TLSA announced positive Phase 2a INFORM-MS trial results and will present at the Jefferies Healthcare Conference.
likely upward pressure as investors price in the favorable trial outcomes
The trial met primary endpoints with statistical significance and safety signals, a material catalyst for a clinical‑stage biotech.
Market effects
Strengthens the neuro‑inflammation biotech niche and may lift peer companies developing intranasal immunotherapies.
Limited to U.S. biotech investors; no broader regional effect.
Modest; primarily relevant to specialty biotech investors.
Counterpoint
If the data cannot be replicated in larger trials, the initial hype may fade.
Key entities
- companyTiziana Life Sciences Ltd.
Biotech developing intranasal foralumab.
- eventJefferies Healthcare Conference
Venue where TLSA will present its data.

